Affiliation:
1. Pharmacology Department, Amrita Institute of Medical Science, Kochi, Kerala, India
Abstract
Abstract
Aprocitentan (TRYVIO), is the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with 3 combined antihypertensive class drugs. Aprocitentan is a dual endothelin receptor antagonist that inhibits the binding of ET-1 to both ETA and ETB receptors. Aprocitentan tablets are available as 12.5 mg orally once daily. It can be administered to subjects with mild and moderate hepatic impairment without the need for dose adjustment. The most frequently reported adverse reactions to during the 4-week double blind placebo-controlled treatment period (part 1) of the PRECISION study is edema and anaemia. Others include embryo-fetal toxicity, hepatotoxicity, fluid retention, hemoglobin decrease, decreased sperm counts. Aprocitentan is contraindicated in pregnancy and in patients who are hypersensitive to aprocitentan or any of its excipients.